



TYPE-1 INTERFERON

Helpful Educational Resources

1. Crow MK, Type 1 Interferon in the Pathogenesis of Lupus, *The Journal of Immunology*. 192(12); 5459-5468 (2014)
2. Arriens C, et al., Increased Risk of Progression to Lupus Nephritis for Lupus Patients with Elevated Interferon Signature[abstract], *Arthritis Rheumatol*. 2019; 71 (suppl 10) <https://acrabstracts.org/abstract/increase-risk-of-progression-to-lupus-nephritis-for-lupus-patients-with-elevated-interferon-signature>
3. Barber M, et al., Economic evaluation of lupus nephritis in the Systemic Lupus International Collaborating Clinics inception cohort using a multistate model approach, *Arthritis Care Res*, 2018 70(9):1294-1302
4. X. Feng, et al., "Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus.," *Arthritis Rheum.*, pp. Sep;54(9):2951-62., (2006)
5. Clowse MEB, et al., A national Study of Complications of Lupus in Pregnancy, *Am. J. Obstet Gynecol*, 199(2):127e1-127e6 (2008)
6. Andrade D, et al., Interferon- α and Angiogenic Dysregulation in Pregnant Lupus Patients Who Develop Preeclampsia, 67(4): 977-987 (2015)
7. Niewold TB, et al., High serum IFN- α activity is a heritable risk factor for systemic lupus erythematosus, *Genes Immun*. 8(6):492-502 (2007)
8. Petri M, et al., Longitudinal Expression of type 1 interferon responsive genes in systemic lupus erythematosus, *Lupus* 18(11):980-989 (2009)
9. E. Baechler, et al., "Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus.," *Proc Natl Acad Sci U S A.*, pp. Mar 4;100(5):2610-5. Epub 2003 Feb 25., (2003)
10. Kirou KA, et al., Activation of the Interferon- α pathway identifies a subgroup of Systemic lupus erythematosus patients with distinct Serologic Features and active disease, *Arthritis Rheum* 52:1491-503 (2005)
11. Lauwerys BR, et al., Type 1 interferon blockade in systemic lupus erythematosus: where do we stand?, *Rheumatology*, 53:1369-1376 (2014)
12. AstraZeneca Press Release 08-29-19, Anifrolumab Phase III trial meets primary endpoint in systemic lupus erythematosus: <https://www.astrazeneca.com/media-centre/press-releases/2019/anifrolumab-phase-iii-trial-meets-primary-endpoint-in-systemic-lupus-erythematosus-29082019.html>

Visit us at www.DxTernity.com

19500 S Rancho Way STE 116, Rancho Dominguez, CA 90220